The FDA has approved a new noninvasive stereotactic radiotherapy system to treat cancer in breast tissue.
Indications: The GammaPod system is intended for use in the noninvasive stereotactic delivery of a radiation dose to a portion of the breast in conjunction with breast conserving treatment.
Administration: The system uses thousands of focused beams of radiation from 36 rotating radioactive Cobalt-60 sources in combination with a 2-layer, vacuum-assisted cup that immobilizes the breast to achieve a more accurate delivery of radiation.
Efficacy and safety: Approval is based on a study of 17 individuals that showed the prescribed dose was delivered to the breast tumor with minimal radiation-induced side effects such as skin redness or erythema.
FDA clears stereotactic radiotherapy system for use in treating breast cancer [news release]. Silver Spring, MD: FDA. December 22, 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm590313.htm... Accessed December 31, 2017.
This Week's Must Reads
Estimated conditional OS shows upfront TKI benefit in mRCC, Kang M et al. J Urol. 2018 June 22. doi: 10.1016/j.juro.2018.06.030
Indolent course found in rare clear cell papillary RCC , Chen W-J et al. J Chinese Med Assoc. 2018 July 20 doi: 10.1016/j.jcma.2018.04.005
Study: Clear cell papillary RCC has indolent course, Chen W-J et al. J Chinese Med Assoc. 2018 July 20 doi: 10.1016/j.jcma.2018.04.005
Some ccRCC subtypes associated with CT features, Bowen L, Xiaojing L. Acad Radiol. 2018 Jul 29. doi: 10.1016/j.acra.2018.05.002
GAG measurements offer prognostic info for RCC, Gatto F et al. Eur Urol Oncol. 2018 Jun 13. doi: 10.1016/j.euo.2018.04.015
Must Reads in Breast Cancer
Study could clarify CTC-based staging of metastatic breast cancer , Davis A et al. ASCO 2018 Poster 1019.
Taselisib and fulvestrant fall short in advanced ER+/HER2- breast cancer, Baselga et al. ASCO Abstract LBA1006.
Brain met outcomes similar for NSCLC, breast cancer patients, Cagney DN et al. JAMA Oncol. 2018 May 17. doi: 10.1001/jamaoncol.2018.0813.
Ketorolac during primary breast cancer surgery bettered diclofenac, Desmedt C et al. J Natl Cancer Inst. 2018 Apr 30. doi: 10.1093/jnci/djy042.
FDA Approves Lynparza for Certain Types of BC, FDA news release; 2018 Jan 12